(US FOOD AND DRUG ADMINISTRATION), United States Regulatory Agency equivalent to Anvisa in Brazil, approved on Wednesday (18.Jun.2025) the injectable drug Yeztugo Lenacapavir for HIV prevention. It is not a cure.
According to the company responsible for the drug, Yeztugo Lenacapavir should be applied twice a year as (pre-exposure prophylaxis), ie to prevent a possible virus infection.
“It’s a historic day for the many decades of combating HIV. Yeztugo is one of the most important scientific discoveries of our time and gives us a real opportunity to help end HIV.”Daniel O’Day, CEO of Gilead Sciences, in a statement.
Gilead Sciences reported that the tests showed an effectiveness of 99.9%, ie almost 100% of participants did not contract HIV after receiving both injections of the drug. The most common adverse reactions recorded were headache and nausea.
Yeztugo Lenacapavir is suitable for adults or adolescents with at least 35 kg as a way to prevent HIV infection. It is necessary to undergo a HIV-1 test before receiving the 1st injection. Only those who have the negative result can make use of the medicine.
In a statement, the WHO (World Health Organization) the FDA authorization. The director of the Global HIV, Hepatitis and STI programs, Meg Doherty, said it was “One Step” on the way to “expand access to an innovative HIV prevention option ”. Currently, 39.9 million people have HIV in the world. The data are from UNAIDS report. Read A (PDF – 171 KB).
